Key statistics
On Monday, Aptargroup Inc (AGT:FRA) closed at 120.40, -14.85% below its 52-week high of 141.40, set on Mar 03, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 120.20 |
|---|---|
| High | 120.60 |
| Low | 120.20 |
| Bid | 121.70 |
| Offer | 122.40 |
| Previous close | 121.70 |
| Average volume | 203.40 |
|---|---|
| Shares outstanding | 64.38m |
| Free float | 63.55m |
| P/E (TTM) | 24.42 |
| Market cap | 9.25bn USD |
| EPS (TTM) | 5.88 USD |
| Annual div (ADY) | 1.63 EUR |
|---|---|
| Annual div yield (ADY) | 1.34% |
| Div ex-date | Feb 04 2026 |
| Div pay-date | Feb 25 2026 |
Data delayed at least 15 minutes, as of Mar 02 2026 10:53 GMT.
More ▼
- Aptar to Participate in Upcoming Investor Conferences
- Aptar Reports Fourth Quarter and Annual 2025 Results
- Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details
- Aptar Again Recognized with Prestigious ‘A’ Score on the CDP Climate Change Assessment
- Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
- Aptar’s Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink™
- Aptar Announces 2026 Quarterly Conference Call Dates
- Aptar Digital Health and ŌURA Collaborate to Advance Migraine Insights by Connecting Migraine Buddy® with Oura Ring
- Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
- Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
More ▼
